Moderna 177% after initial melanoma results showed its personalized vaccine with Merc
Feedback
Melaporkan
0 Ditonton Premium12 jam yang lalu
Moderna surged 177% after initial melanoma results showed its personalized vaccine with Merck's Keytruda outperformed Keytruda alone in recurrence-free and metastasis-free survival. The companies did not disclose the duration of that benefit or whether patients lived longer overall.
Dilarang memposting ulang tanpa izin dari Kreator.
Moderna surged 177% after initial melanoma results showed its personalized vaccine with Merck's Keytruda outperformed Keytruda alone in recurrence-free and metastasis-free survival. The companies did not disclose the duration of that benefit or whether patients lived longer overall.